Aktuellt
SENASTE
Redeye revisits the Alzinova equity story following the company’s continued pipeline progress and recent rights issue. We continue to see the lead candidate, ALZ-101, as a candidate that stands out from other Alzheimer’s treatments. We argue that Alzinova offers an exciting investment opportunity and see an attractive entry point for the long-term oriented investor.
LÄS MER
